# Clinical Trials Data EGFR - Document 99

# Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT00940316

"eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n\* Histologically confirmed colorectal cancer\n\n \* Metastatic disease\n\n \* Biopsy of either the primary cancer or metastatic site required\n \* Tumor expressing wild-type Kras mutations\n\* Progressive disease within 3 months after treatment with first-line fluorouracil (5-FU) and oxaliplatin-based chemotherapy OR evidence of metastatic disease within 6 months of completing adjuvant therapy with 5-FU and oxaliplatin\n\* Measurable disease defined as \u2265 1 lesion that can be accurately measured in \u2265 1 dimension (longest diameter to be recorded) as \u2265 20 mm with conventional techniques OR as \u2265 10 mm with spiral CT scan\n\nPATIENT CHARACTERISTICS:\n\n\* ECOG performance status 0-2\n\* Life expectancy \\> 6 months\n\* ANC \\> 1,500/mm\\^3\n\* Platelet count \\> 100,000/mm\\^3\n\* Hemoglobin \u2265 9 g/dL\n\* Creatinine \\< 1.5 times upper limit of normal (ULN)\n\* Bilirubin \\< 1.5 times ULN (or \\< 2 mg/dL)\n\* AST and/or ALT \\< 3 times ULN (\\< 5 times ULN with liver metastases)\n\* Not pregnant or nursing\n\* Negative pregnancy test\n\* Fertile patients must use effective contraception\n\* No concurrent malignancy requiring therapy except minor surgery for non-melanoma skin cancer removal\n\* No interstitial lung disease with symptoms (e.g., dyspnea or cough) including any of the following significant conditions:\n\n \* Parenchymal lung disease\n \* Metastatic disease\n \* Pulmonary infections\n\nPRIOR CONCURRENT THERAPY:\n\n\* See Disease Characteristics\n\* No prior EGFR inhibitors, irinotecan hydrochloride, or other second-line chemotherapy regimens\n\* More than 4 weeks since prior radiotherapy\n\* No other concurrent investigational agents\n\* No other concurrent anticancer treatment modalities (e.g., radiotherapy)",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
No. The patient would \*not\* be eligible. The eligibility criteria specifically require "Tumor expressing \*\*wild-type Kras mutations\*\*". This means the patient \*cannot\* have other mutations like EGFR mutations in the Kras gene. The trial is looking for patients with colorectal cancer that \*don't\* have Kras mutations.